NOWAK has been 100% owned by MARLE GROUP since December 2023.

When was NOWAK acquired by MARLE GROUP?

NOWAK was acquired by MARLE GROUP in 2023.

What was the revenue of NOWAK at the time of the deal?

The revenue of NOWAK at the time of the deal is estimated to be in the range of 25M - 50M EUR.

How is the data for the NOWAK acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the NOWAK deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/sortie/nowak-repris-par-marle-group-2040724

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaNOWAK

12/2023

NOWAK acquired by MARLE GROUP

FRANCE Life Sciences / Medical Devices / Implants & Prosthetics REV 25M - 50M EUR

Context

Marle Group has acquired Nowak from a consortium of private equity investors led by Siparex Midcap, alongside Bpifrance, Unexo, and the management team. This acquisition strengthens Marle's vertical integration by adding specialized casting capabilities. The deal follows a successful transformation period under Siparex (2018-2023), where Nowak shifted its focus toward the medical sector and acquired Belmonte. The transaction was financed via a unitranche debt facility provided by Capza.

NOWAK, which reported an EBITDA margin of in 2023, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 1984, Nowak is a premier French specialist in "lost-wax" precision casting (investment casting). Originally a generalist foundry, the company successfully pivoted towards the medical sector, which now accounts for 50% of its sales. It manufactures complex metal parts for orthopedic implants (knees, hips, shoulders) and medical instruments. The company also serves demanding Corporate sectors such as energy, luxury goods, and Corporate valves. Following the acquisition of Belmonte in 2021, Nowak grew its revenue to EUR30 million.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2023

2022

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
03/2024	ADVANCED MEDICAL SOLUTIONS GROUP	PÉTERS SURGICAL	FRANCE	Medical Consumables
01/2024	MERCK & CO.	HARPOON THERAPEUTICS	UNITED STATES	R&D Biotech
11/2023	ANJAC BEAUTY & HEALTH	STEPHID	FRANCE	CDMO
11/2023	AMETEK	PARAGON MEDICAL	UNITED STATES	Medical Devices
10/2023	LUXEMPART	ALPHACAPS	GERMANY	Nutrition & Dietary Supplements
10/2023	RESONETICS	NITINOL BUSINESS	UNITED STATES	Medical Devices
08/2023	CARL ZEISS MEDITEC	D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)	NETHERLANDS	Medical Devices
08/2023	OAKLEY CAPITAL INVESTMENTS	LIBERTY DENTAL GROUP	GERMANY	Implants & Prosthetics
08/2023	ATHOS CONSORTIUM	SCHÜLKE	GERMANY	Medical Consumables
07/2023	EQT PARTNERS / ADIA	DECHRA PHARMACEUTICALS	UNITED KINGDOM	Pharma & Biotech

REFERENCES

Revenue range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NOWAK by MARLE GROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: nowak

Acquirer: marle group